drugset
drugset / Trial / NCT04260438

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects

NCT04260438 ↗

Phase 1 Completed 24 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This study is an open-label, randomized, fed, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-393 in healthy subjects

Timeline

Start
2020-04-08
Primary completion
2020-06-15
Completion
2020-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-393 Unknown 0.5 mg Oral
Subject CKD-393 Unknown 100 mg Oral
Subject CKD-393 Unknown 1000 mg Oral
Subject D150 Unknown 1000 mg Oral
Subject D759 Unknown 100 mg Oral
Subject Lobeglitazone Small molecule 0.5 mg Oral

Indications

type 2 diabetes mellitus